Early day motion tabled by primary sponsor Jim Shannon (Democratic Unionist Party), on Tuesday, 17 July 2018, in the House of Commons. It is signed by 35 members in total.
NEW MEDICINE FOR NEUROBLASTOMA
That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend dinutuximab beta for the treatment of children with high-risk neuroblastoma; praises the collaborative and flexible approach of all parties including NICE, EUSA Pharma, Solving Kids' Cancer, Neuroblastoma UK, the Children's Cancer and Leukaemia group, JACK, the Bradley Lowery Foundation, Hugs from Henry, Christopher's Smile, Niamh's Next Steps and Smile with Siddy, Grace Kelly Ladybird Trust, Rupert's Revenge Trust, Stacey's Smiles, Harvey Hext Trust, George and the Giant Pledge and Abbie's Army; notes the dedication and involvement of the clinical community in supporting the appraisal process; and calls on the House to praise the bravery of all those children suffering from high-risk neuroblastoma in the UK today.
Secondary information
- Type
- Early day motion
- Reference
- 1531
- Session
- 2017-19
- Other sponsors
- Gregory Campbell
- Angus Brendan MacNeil
- David Simpson
- Gavin Newlands
- Paul Girvan
- Subjects
- Children Health services Diseases Medicine
- Link
- View this Early day motion on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-10-06 21:10:01 +0100
- URI
- http://data.parliament.uk/edms/52002
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/edms/52002
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/edms/52002